A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
Status:
Terminated
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
Prospective, multicenter, phase II clinical trial to determine the efficacy of plitidepsin in
patients with relapsed/refractory (R/R) angioimmunoblastic Tcell lymphoma (AITL).This is an
international, multicenter study (with approximately 17 investigative sites).